Drugs / QLS1128
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05458076 | Jul → Sep 2022 | COVID-19 | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05689203 | Dec 2022 → Feb 2023 | COVID-19 | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05758519 | Mar → Jun 2023 | COVID-19 | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS1128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05758519 ↗ |
| Route | Oral | “administered orally” NCT05689203 ↗ |